Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 19/20 | 0.58 |
| ▸ | PRAP1 | Q96NZ9 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | TNKS | O95271 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | PARP6 | Q2NL67 | 1/20 | 0.47 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.47 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.47 |
| ▸ | PARP8 | Q8N3A8 | 1/20 | 0.47 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.47 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 0.47 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.47 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4088922 | 0.92 | PARP1 (0.59) | PARP1PRAP1TNKSADORA1CDK6 | |
| SCHEMBL4104414 | 0.91 | PARP1 (0.57) | PARP1PRAP1TNKSADORA1CDK6 | |
| SCHEMBL4096575 | 0.90 | PARP1 (0.56) | PARP1PRAP1CYP3A4CYP2C9TSHR | |
| SCHEMBL4094897 | 0.90 | PARP1 (0.56) | PARP1PRAP1TNKSADORA1CDK6 | |
| SCHEMBL3633762 | 0.88 | PARP1 (0.62) | PARP1PRAP1CYP3A4CYP2C9TSHR | |
| SCHEMBL14028998 | 0.88 | PARP1 (0.62) | PARP1PRAP1CYP3A4CYP2C9TSHR | |
| SCHEMBL4096198 | 0.88 | PARP1 (0.54) | PARP1PRAP1TNKSTNKS2 | |
| SCHEMBL3630956 | 0.83 | PARP1 (0.61) | PARP1 | |
| SCHEMBL14029001 | 0.83 | PARP1 (0.61) | PARP1 | |
| Hydrochloric Acid SCHEMBL3636680 | 0.82 | PARP1 (0.60) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011058367-A2 | DIAGNOSTIC TEST FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR | ASTRAZENECA AB (SE) | 2011-05-19 | — | — | WO | disclosed |
| US-7902193-B2 | Phthalazinone derivatives | MAYBRIDGE LIMITED (GB) | 2011-03-08 | — | — | US | disclosed |
| US-7902193-B2 | Phthalazinone derivatives | MAYBRIDGE LIMITED (GB) | 2011-03-08 | — | — | US | disclosed |
| US-7902193-B2 | Phthalazinone derivatives | MAYBRIDGE LIMITED (GB) | 2011-03-08 | — | — | US | disclosed |
| US-20090069303-A1 | PHTHALAZINONE DERIVATIVES | MAYBRIDGE LIMITED (GB) | 2009-03-12 | — | — | US | disclosed |
| US-20090069303-A1 | PHTHALAZINONE DERIVATIVES | MAYBRIDGE LIMITED (GB) | 2009-03-12 | — | — | US | disclosed |
| US-20090069303-A1 | PHTHALAZINONE DERIVATIVES | MAYBRIDGE LIMITED (GB) | 2009-03-12 | — | — | US | disclosed |
| US-7470688-B2 | Phthalazinone derivatives | MAYBRIDGE LIMITED (GB) | 2008-12-30 | — | — | US | disclosed |
| US-7470688-B2 | Phthalazinone derivatives | MAYBRIDGE LIMITED (GB) | 2008-12-30 | — | — | US | disclosed |
| US-7470688-B2 | Phthalazinone derivatives | MAYBRIDGE LIMITED (GB) | 2008-12-30 | — | — | US | disclosed |
| CN-101291928-A | 4-heteroarylmethyl-substituted phthalazinone derivatives | KUDOS PHARM LTD MAYBRIDGE LTD (GB) | 2008-10-22 | — | — | CN | disclosed |
| EP-1948642-A1 | 4-HETEROARYMETHYL SUBSTITUTED PHTHALAZINONE DERIVATIVES | Kudos Pharmaceuticals Ltd (GB) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007045877-A1 | 4-HETEROARYMETHYL SUBSTITUTED PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007045877-A1 | 4-HETEROARYMETHYL SUBSTITUTED PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-04-26 | — | — | WO | disclosed |
| US-20070093489-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-04-26 | — | — | US | disclosed |
| US-20070093489-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-04-26 | — | — | US | disclosed |
| US-20070093489-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069303-A1 | PHTHALAZINONE DERIVATIVES | NR2C2, NR2E3, NR3C2 | PARP1 2875/4885PRAP1 2054/4885CYP3A4 1684/4885 |
| US-20070093489-A1 | PHTHALAZINONE DERIVATIVES | NR2C2, NR2E3, NR3C2 | PARP1 2388/4885PRAP1 2011/4885CYP3A4 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.